12:00 AM
Aug 12, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AZD8330: Development discontinued

AstraZeneca disclosed in its 2Q13 earnings that it discontinued development of AZD8330 for solid tumors. The pharma cited "safety/efficacy" as...

Read the full 77 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >